PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Fully Human Monoclonal Antibodies for Targeted Cancer Therapy Development

Abstract 5646: Fully human monoclonal antibodies for antibody drug conjugate development to a cell surface target expressed in cancers with unmet needs.

View Full Paper

Authors

GSGinette SerreroJMJorge MarquezJDJianping Dong

Discussion

Loading...

Member takes

Overview

Research identifies PTGFRN as a promising target for antibody drug conjugates, suggesting new therapies for cancers with unmet needs.

Key Points

  • The aim is to develop targeted therapies by identifying cell surface targets overexpressed in cancers with poor prognosis.
  • Identified PTGFRN as an internalizing, overexpressed protein in cancers.
  • Developed fully human monoclonal antibodies using humanized transgenic mice.
  • Conducted screening assays to select high-affinity internalizing antibodies.
  • Tested antibody-drug conjugates (ADCs) in vitro and in vivo for efficacy.
  • PTGFRN was associated with key steps in cancer metastasis.
  • ADCs demonstrated efficacy in inhibiting cancer cell proliferation and tumor formation.
  • No effect was observed on PTGFRN negative human cell lines.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Serrero et al. (2026) studied this question.

synapsesocial.com/papers/69d1fe07a79560c99a0a4783https://doi.org/10.1158/1538-7445.am2026-5646
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 4695: Effect of fully human anti-PTGFRN antibody drug conjugate on head neck cancer cells and patient derived xenografts2024
  2. 2Abstract 5833: Therapeutic targeting of adhesion receptor GPR56 for the treatment of triple-negative breast cancer2026
  3. 3Abstract 2613: Treatment of solid tumors with antibody drug conjugates targeting aberrant O-glycoproteins2024 · 1 citations
  4. 4Abstract 2630: MRG008: A novel EGFR and 5T4 bispecific antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies.2026
  5. 5Abstract 1864: New generation of fully human anti-progranulin monoclonal antibodies inhibiting migration and tumor formation of non-small cell carcinoma cells2024